Reference - Detail
|Author||Kuwashiro S, Terai S, Oishi T, Fujisawa K, Matsumoto T, Nishina H, Sakaida I.|
|Title||Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation.|
|Journal||Cell Tissue Res.|
We investigated the efficacy of the antihypertensive drug telmisartan (Tel) and the mechanisms underlying the progression from simple steatosis to nonalcoholic steatohepatitis (NASH) in a medaka (Oryzias latipes) NASH model. We used the NASH activity score (NAS) developed in humans to assess the histology of the medaka NASH model and found that NAS increased with time. Further, TUNEL-positive apoptosis hepatocytes were found in the medaka NASH model. Tel administration resulted in the increased expression of liver peroxisome proliferator-activated receptor-γ, carnitine palmitoyltransferase 1 and acyl-CoA oxidase 1 and decreased the number of 8-hydroxydeoxyguanosine-positive hepatocytes and the migration of macrophages positive for diastase-periodic-acid-Schiff. Medaka NAS was improved by Tel administration but fatty acid content was not affected. Tel reduced the infiltration of macrophages into the liver and ameliorated NASH pathology.
|MeSH||Angiotensin II Type 1 Receptor Blockers / therapeutic use* Animals Antihypertensive Agents / therapeutic use* Benzimidazoles / therapeutic use* Benzoates / therapeutic use* Carnitine O-Palmitoyltransferase / genetics Cell Movement / drug effects Disease Models, Animal* Fats / metabolism* Fatty Liver / drug therapy Fatty Liver / genetics Fatty Liver / metabolism Fatty Liver / pathology Gene Expression / drug effects Humans Macrophages / drug effects* Non-alcoholic Fatty Liver Disease Oryzias / metabolism* Oxidative Stress PPAR gamma / genetics Weight Gain / drug effects|
|WOS Category||CELL BIOLOGY|
|Medaka||OK-Cab (MT830) hi-medaka (MT835)|